Antibody-Drug Conjugates
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
ADCs: Global market intelligence for investors & BD. Stay ahead on novel payloads, linker tech, and clinical trial updates for antibody-drug conjugates.
Showing 1–6 of 6 articles
Quick answer
NovaPharmaNews Antibody-Drug Conjugates hub for NMPA covers 6 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Huahui Health Partners with BeOne Medicines for HH160 Trispecific Antibody in Global Oncology Deal
Alphamab Oncology JSKN016 TROP2/HER3 Bispecific ADC Shows Promise for HER2-Negative Breast Cancer at ASCO 2026
Kelun-Biotech's Sacituzumab Tirumotecan and Two Other Cancer Drugs Selected for ASCO 2026 Oral Presentations
Antengene Presents Three Novel Cancer Programs at AACR 2026: Next-Generation ADC and TCE Therapies Show Promise
Antengene Presents Next-Generation ADC and AnTenGager TCE Programs at AACR 2026
Phrontline Biopharma's TJ106 Shows Promise Against HER2-Low and Drug-Resistant Cancers in Preclinical Studies
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.